Clinical trial • Phase I/II • Oncology
Olaparib for Glioblastoma
Phase I/II trial of Olaparib for Glioblastoma. 91 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Glioblastoma
- Trial Stage
- Phase I/II
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 16-09-2024
- First CTIS Authorization Date
- 08-11-2024
Trial design
Phase I/II trial across 13 sites in France.
- Target Sample Size
- 91
- Trial Duration For Participant
- 365
Eligibility
Recruits 91 No vulnerable populations selected..
- Vulnerable Population
- No vulnerable populations selected.
Recruitment
- Planned Sample Size
- 91
- Recruitment Window Months
- 12
Geography
- Total Number Of Sites
- 13
- Total Number Of Participants
- 91
France
- Earliest CTIS Part Ii Submission Date
- 16-09-2024
- Latest Decision Or Authorization Date
- 20-04-2026
- Processing Time Days
- 581
- Number Of Sites
- 13
- Number Of Participants
- 91
Sites
- Site Name
- Centre Leon Berard
- Department Name
- Radiotherapy
- Contact Person Name
- Marie-Pierre- SUNYACH
- Contact Person Email
- marie-pierre.sunyach@lyon.unicancer.fr
- Site Name
- Centre Francois Baclesse
- Department Name
- Radiotherapie
- Contact Person Name
- Dinu STEFAN
- Contact Person Email
- d.stefan@baclesse.unicancer.fr
- Site Name
- Groupe Hospitalier Du Havre
- Department Name
- Oncology department
- Contact Person Name
- Violette ALLOUCHERY
- Contact Person Email
- violette.allouchery@ch-havre.fr
- Site Name
- Centre Henri Becquerel
- Department Name
- Centre Onclogie Medicale
- Contact Person Name
- Cristina ALEXANDRU
- Contact Person Email
- cristina.alexandru@chb.unicancer.fr
- Site Name
- Groupe Hospitalier Bretagne Sud
- Department Name
- Oncology
- Contact Person Name
- Edwina GIRARD
- Contact Person Email
- e.girard@ghbs.bzh
- Site Name
- Institut Curie
- Department Name
- Radiotherapy department
- Contact Person Name
- Hamid MAMMAR
- Contact Person Email
- hamid.mammar@curie.fr
- Site Name
- Institut De Cancerologie De L Ouest
- Department Name
- Oncology department
- Contact Person Name
- Pierre KUBICEK
- Contact Person Email
- pierre.kubicek@ico.unicancer.fr
- Site Name
- Oncopole Claudius Regaud
- Department Name
- Radiotherapy department
- Contact Person Name
- Elisabeth MOYAL
- Contact Person Email
- moyal.elisabeth@iuct-oncopole.fr
- Site Name
- CHU De Bordeaux
- Department Name
- Service Oncologie Médicale
- Contact Person Name
- Charlotte BRONNIMANN
- Contact Person Email
- charlotte.bronnimann@chu-bordeaux.fr
- Site Name
- Institut De Cancerologie De L Ouest
- Department Name
- Service Oncologie-Radiothérapie
- Contact Person Name
- Carole GOURMELON
- Contact Person Email
- carole.gourmelon@ico.unicancer.fr
- Site Name
- Hopitaux Universitaires Pitie Salpetriere
- Department Name
- Service Oncologie-Radiothérapie
- Contact Person Name
- Julian JACOB
- Contact Person Email
- julian.jacob@aphp.fr
- Site Name
- Centre De Radiotherapie Guillaume Le Conquerant
- Department Name
- Radiotherapie
- Contact Person Name
- Paul LESUEUR
- Contact Person Email
- p.lesueur@cglc.fr
- Site Name
- CHU De Medecine Interne
- Department Name
- Service Oncologie Médicale
- Contact Person Name
- Mathieu BOONE
- Contact Person Email
- boone.mathieu@chu-amiens.fr
Sponsor
Primary sponsor
- Full Name
- Centre Francois Baclesse
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- Olaparib
- Active Substance
- Olaparib
- Modality
- Small molecule
- Investigational Product Name
- Temozolomide
- Active Substance
- Temozolomide
- Modality
- Small molecule
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.